ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zai Lab Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.06+0.87 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Zai Lab Ltd revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZEJULA | $160.52M | $169.48M | $189.04M | $181.36M | $187.15M | $191.11M | $187.08M | $180.34M | $173.71M | $171.66M | $168.84M | $169.56M | 35.7% | -14.2% |
| VYVGART / VYVGART Hytrulo | $91.01M | $93.64M | $94.20M | $102.35M | $101.89M | $98.58M | $93.64M | – | – | – | – | – | 20.2% | -10.7% |
| NUZYRA | $64.79M | $61.98M | $60.84M | $55.83M | $50.40M | $48.40M | $43.20M | $38.27M | $33.76M | $26.10M | $21.66M | $17.19M | 14.4% | +28.5% |
| OPTUNE | $48.88M | $49.03M | $48.33M | $44.07M | $39.13M | $39.36M | $40.48M | $41.15M | $45.00M | $46.11M | $46.97M | $50.87M | 10.9% | +24.9% |
| QINLOCK | $37.14M | $36.09M | $35.61M | $33.00M | $32.74M | $31.24M | $28.83M | $26.48M | $23.54M | $24.03M | $19.24M | $20.37M | 8.3% | +13.5% |
| XACDURO | $33.70M | $30.37M | $22.91M | $15.49M | $9.04M | $4.42M | $3.31M | – | – | – | – | – | 7.5% | +272.6% |
| AUGTYRO | $6.52M | $5.70M | $5.54M | $5.79M | $4.11M | $2.71M | $1.09M | – | – | – | – | – | 1.4% | +58.5% |
| Other | $644.00K | $791.00K | $717.00K | $717.00K | $625.00K | $283.00K | $0 | – | – | – | – | – | 0.1% | +3.0% |
| VYVGART / VYVGART Hytrulo | – | – | – | – | – | – | – | $68.69M | $46.31M | $23.17M | $10.01M | $4.94M | – | – |
By region
From the segment and revenue-disaggregation notes of Zai Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.